급성 골수성 백혈병 등 혈액암 노인 환자를 대상으로 원격진료 프로그램이 의료 소통과 불안, 서류 작성을 돕는지 확인하는 초기 시험입니다.

The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).

Telehealth Serious Illness Care Program

Education materials developed by the NCI on "Communication in Cancer Care (PDQ®) - Patient Version"

Education Control

Kah Poh Loh, MD

다발성 골수종 환자의 감염 예방을 위한 새로운 항체 치료의 효과와 안전성을 평가하는 중재적 임상시험입니다.

Immunoglobulin support (subcutaneous or intravenous)

Target trough IgG level of 8-10 g/L

Immunglobulin support (subcutaneous or intravenous)

Target trough IgG level 4-6 g/L

No immunoglobulin support. If pre specified conditions are met, crossover to Group A or B.

If, during follow-up, the patient presents recurrent or severe infections and/or total IgG level less 4 g/L, crossover to group A or B

No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L

Frederic Larose, MD

Martn Rochette

Philippe Nadeau, PhD

Julie Côté, MD, FRCPC

Adult patients across all phases of advanced disease (UICC stage IV solid tumor) from diagnosis to terminal stages

A short-term psychodynamic therapy that focuses on the special inner and outer situation of patients with a serious physical illness, especially with regard to the importance of relationships in a limited lifetime.

Short-term psychodynamic psychotherapy for patients with serious physical illness (ORPHYS)

Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.

Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies.

Adults with Alzheimer's disease

Adults with Myasthenia

Frozen spinal fluid of 10 healthy controlled stored in a biobank in Munster, Germanywill be compared to the ones of Adults with Myasthenia and Adults with Alzheimer's disease

Healhty controls

Justine LEMAIRE

Guillaume SACCO, MD

신경 및 대사 질환 환자의 움직임을 2년간 웨어러블 기기로 관찰하여 미래 임상시험을 위한 유용한 데이터 수집을 목표로 합니다.

Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.

Syde

This test consists of covering the greatest possible distance within 6 minutes, walking back and forth along a 25-meter hallway. The subject may stop if they need to. The evaluator will record the elapsed time after each half-lap, and the final distance that was covered at the end of the test. No help will be allowed during the test.

The 6-minute walk test (6MWT)

During this test, the subject must cover a distance of 10 meters as rapidly as possible. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test. No help will be allowed during the test.

The 10-meter test (10MWT)

This is a standardized test during which the subject must climb the 4 stair steps as rapidly as possible. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test, or more if needed.

The 4 stair-climbing test (4SC)

This is a standardized test during which the subject must rise from the floor as rapidly as possible. The test starts with the participant lying on their back. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test.

Test of rising from the floor (TRF)

PGIC is a patient-reported scale used to assess how a patient feels their condition has changed over time. It typically uses a 7-point scale to capture the patient's overall perception of improvement in symptoms, function, and quality of life.

Patient's Global Impression of Change (PGIC)

Dynamometric measurements of the maximum force of the following functions will be taken with the MyoTools: palmar grip (MyoGrip) and thumb-index pinch (MyoPinch). Test will be realized on the dominant side. Patients will be encouraged during the test. They will be given three trials and the best score will be entered.

Dynamometric measurements of muscle strength

The CMTES is a 28-point composite score that rates the patient's symptoms and signs. It is part of the Charcot-Marie-Tooth (CMT) neuropathy score and has been validated as a reproducible measure of disability in CMT. Higher scores indicate more severe neuropathy.

The Charcot-Marie-Tooth examination score (CMTES)

The 9-HPT is a quantitative test of upper limb function. It is the second component of the Multiple Sclerosis Functional Composite (MSFC). The patient sits at a table with a shallow container containing nine sticks and a wooden or plastic block containing nine empty holes. When a timer is started, the patient places the nine sticks one after the other as quickly as possible into the nine holes and, once they are all in the holes, removes them as quickly as possible. The total time taken to complete the task is recorded. Two consecutive attempts with the dominant hand are immediately followed by two consecutive attempts with the non-dominant hand.

9-Hole Peg Test (9-HPT)

This 8-item scale was developed to assess ataxia severity and disease progression. It evaluates gait and balance, speech, and upper and lower limb coordination. The score ranges from 0 to 40, with higher score indicating a worse clinical outcome.

The Scale for the Assessment and Rating of Ataxia (SARA)

This 74-item clinical rating scale assesses patient performance and capacity in 4 domains: motor function, cognitive function, behavioral abnormalities, and functional capacity.

The Unified Huntington's Disease Rating Scale (UHDRS)

During this standardized test, the subject is observed and timed while he/she rises from a chair, walks 3 meters, performs a 180° turn, walk back toward the chair and sits down.

The Timed up and go test (TUG)

This 28-item clinician-rated scale assesses motor and non-motor symptom severity in patients with PSP, with a score ranging from 0 (normal) to 100.

The Progressive Supranuclear Palsy Rating Scale (PSP-RS)

The MOCA was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MOCA range from 0 to 30, with higher score being better outcome.

The Montreal Cognitive Assessment (MOCA)

The QMG is a clinician-rated 13-item scale used to quantify disease severity in patients with MG. The scale grades each domain (ocular, bulbar, respiratory, and limb function), with a total score ranging from 0 to 39 (lower score indicating a better clinical outcome).

Quantitative Myasthenia Gravis (QMG)

This is an 8-item patient-reported scale assessing MG symptoms and their effects on daily activities. The score ranges from 0 to 24, with higher score indicating a worse clinical outcome.

The Myasthenia Gravis Activities of Daily Living Scale (MG-ADL)

6분 걷기 테스트(6MWT)

10m 테스트(10MWT)

4계단 오르기 테스트(4SC)

바닥에서 일어나는 테스트(TRF)

환자의 변화에 대한 전반적인 인상(PGIC)

근력의 동력학적 측정

샤르코-마리-투스 시험 점수(CMTES)

9홀 페그 테스트(9-HPT)

운동실조 평가 및 등급 척도(SARA)

통합 헌팅턴병 평가 척도(UHDRS)

시간 제한 테스트(TUG)

진행성 초핵성 마비 평가 척도(PSP-RS)

몬트리올 인지 평가(MOCA)

정량적 중증 근무력증(QMG)

중증 근무력증 일상생활활동척도(MG-ADL)

Centre Hospitalier Universitaire de Liege

Nicolas Bovy

Laurent Servais, MD

신경학적 또는 대사적 병리를 가진 성인 환자의 보행 분석 매개변수 및 상지 평가

중등도에서 중증 류마티스 관절염 환자를 대상으로 두 가지 약물 조합의 효과를 비교하는 시험입니다.

This intervention is open label. Both patient and investigator will know about the intervention. Participants are allocated according to block randomization. Total two groups with each contain 48 patients. One group will be given Tofacitinib, Methotrexate and another group will be given Upadacitinib, Methotrexate

To see the efficacy of Upadacitinib, Methotrexate versus Tofacitinib, Methotrexate in moderate to severe Rheumatoid arthritis

중등도에서 중증 류마티스 관절염에서 우파다시티닙, 메토트렉세이트와 토파시티닙, 메토트렉세이트의 효능을 비교하려면

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

중등도에서 중증 류마티스 관절염에서 토파시티닙과 메토트렉세이트 병용 요법의 효능과 우파다시티닙과 메토트렉세이트 병용 요법의 효능 비교

Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups

Treadmill

injection of Botulinum Toxin in the two groups of CD and BS

Botulinum Toxin injection

Severity scale of the disease

CD age- and sex-matched healthy control subjects

BS age- and sex-matched healthy control subjects

Patients suffering from lung cancer and treated with paclitaxel

Assessment of blood concentrations of microRNAs

Chemotherapy-induced peripheral neuropathy (CIPN) - grade

Pain assessement

Assessment of blood concentrations of neurofilament light chain

Neuropathic pain assessment

Chemotherapy-induced peripheral neuropathy (CIPN) - severity

Patients suffering from colorectal cancer and treated with oxaliplatin

Lise LACLAUTRE

David BALAYSSAC

This test consists of a set of small manoeuvres (lifting a box, writing, etc.) designed to evaluate the upper-limb functionality of non-ambulatory patients. It was developed specifically for use in cases of Duchenne muscular dystrophy.

Performance of the Upper Limb (PUL) Test

The Brooke Upper Extremity Functional Rating Scale will be used to assess the global functional level of upper limb involvement. This 6-point ordinal scale classifies patients according to their highest achievable upper limb function, from full arm abduction to absence of useful hand function.

Brook test

Forced Vital Capacity (FVC) will be assessed using standardized spirometry procedures. The primary parameter will be FVC expressed as percentage of predicted values. At least three acceptable and reproducible maneuvers will be performed according to standard guidelines.

Forced Vital Capacity (FVC) test

The CGI-S is a clinician-rated scale used at baseline to assess the overall severity of the participant's condition, based on all available clinical information. The rating reflects the clinician's judgment without standardized scoring rules and must be performed by a clinician experienced in Duchenne Muscular Dystrophy. The CGI-S evaluates three domains: physical motor function, respiratory function, and bulbar function. It is completed after all other study assessments (excluding patient-reported outcomes) to ensure a comprehensive evaluation.

Clinical Global Impression - Severity (CGI-S)

The CGI-C is used at each follow-up visit to assess changes in the participant's condition relative to baseline. It provides a clinician-determined measure of improvement or worsening, based on overall clinical judgment rather than fixed criteria. Like the CGI-S, it covers physical motor, respiratory, and bulbar domains and is performed after all other study assessments (excluding patient-reported outcomes). The CGI-C is expected to track consistently with prior CGI-S evaluations, reflecting changes in disease status over time.

Clinical Global Impression - Improvement (CGI-C)

The PGI-S (Patient Global Impression of Severity) is a simple, validated, single-item self-administered scale used to assess the current severity of a patient's condition. Widely used in clinical trials, it allows patients to rate their condition, on a 4- to 6-point scale (from 'Normal' to 'Very severe').

원격진료를 이용한 중증질환 관리 프로그램, 교육 관리

목표 최저 IgG 수치 8-10g/L, 목표 최저 IgG 수치 4-6g/L, 재발성 또는 중증 감염 병력 없음, 총 IgG 수치 4g/L 이상

중증 신체 질환 환자를 위한 단기 정신역동 심리치료(ORPHYS)

알츠하이머병 성인, 중증근무력증 성인, 건강한 대조군

신경학적 또는 대사적 병리를 가진 성인 환자의 보행 분석 매개변수 및 상지 평가

중등도에서 중증 류마티스 관절염에서 토파시티닙과 메토트렉세이트 병용 요법의 효능과 우파다시티닙과 메토트렉세이트 병용 요법의 효능 비교

러닝머신, 보툴리눔 독소 주사, 질병의 중증도 척도

혈중 마이크로RNA 농도 평가, 항암화학요법 유발 말초신경병증(CIPN) - 등급, 통증 평가, 혈중 신경섬유 경쇄 농도 평가, 신경병성 통증 평가, 항암화학요법 유발 말초신경병증(CIPN) - 중증도

상지 기능 검사(PUL 검사), 브룩 검사, 근력 동역학 측정, 강제 폐활량(FVC) 검사, 임상 전반적 인상 - 중증도(CGI-S), 임상 전반적 인상 - 개선도(CGI-C), 환자 전반적 인상 - 중증도(PGI-S), 사이드 검사